IMP3 RNP Safe Houses Prevent miRNA-Directed HMGA2 mRNA Decay in Cancer and Development

Cell Reports

Volumn 7, Issue 2, 2014, Pages 539-551

  Jønson, Lars ^a   Christiansen, Jan ^a   Hansen, Thomas V O ^a   Vikeså, Jonas ^a   Yamamoto, Yohei ^b   Nielsen, Finn C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AKITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; IMP3 RNA BINDING PROTEIN; MICRORNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; IMP3 PROTEIN, HUMAN; LIN28B PROTEIN, HUMAN; MESSENGER RNA; MIRNLET7 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO DEVELOPMENT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIMB DEVELOPMENT; LIN28B GENE; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTO ONCOGENE; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; TUMOR GROWTH; UPREGULATION; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; RNA STABILITY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; MICRORNAS; NEOPLASMS; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84899644869     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.03.015     Document Type: Article

References (69)

1. Beljan Perak R., Durdov M.G., Capkun V., Ivcevic V., Pavlovic A., Soljic V., Peric M. IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn. Pathol. 2012, 7:165.
2. Bellezza G., Cavaliere A., Sidoni A. IMP3 expression in non-small cell lung cancer. Hum. Pathol. 2009, 40:1205-1206.
3. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
4. Boyerinas B., Park S.M., Shomron N., Hedegaard M.M., Vinther J., Andersen J.S., Feig C., Xu J., Burge C.B., Peter M.E. Identification of let-7-regulated oncofetal genes. Cancer Res. 2008, 68:2587-2591.
5. Brants J.R., Ayoubi T.A., Chada K., Marchal K., Van de Ven W.J., Petit M.M. Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett. 2004, 569:277-283.
6. Chen S.T., Jeng Y.M., Chang C.C., Chang H.H., Huang M.C., Juan H.F., Hsu C.H., Lee H., Liao Y.F., Lee Y.L., et al. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma. Cancer Sci. 2011, 102:2191-2198.
7. Chen Y.L., Jeng Y.M., Hsu H.C., Lai H.S., Lee P.H., Lai P.L., Yuan R.H. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma. Int. J. Surg. 2013, 11:85-91.
8. Chiappetta G., Avantaggiato V., Visconti R., Fedele M., Battista S., Trapasso F., Merciai B.M., Fidanza V., Giancotti V., Santoro M., et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996, 13:2439-2446.
9. Christiansen J., Kolte A.M., Hansen Tv., Nielsen F.C. IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes. J.Mol. Endocrinol. 2009, 43:187-195.
10. Cleynen I., Van de Ven W.J. The HMGA proteins: a myriad of functions (Review). Int. J. Oncol. 2008, 32:289-305.
11. Dogar A.M., Semplicio G., Guennewig B., Hall J. Multiple microRNAs derived from chemically synthesized precursors regulate thrombospondin 1 expression. Nucleic Acid Ther. 2014, Published online January 20, 2014. 10.1089.
12. Elcheva I., Goswami S., Noubissi F.K., Spiegelman V.S. CRD-BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation. Mol. Cell 2009, 35:240-246.
13. Findeis-Hosey J.J., Yang Q., Spaulding B.O., Wang H.L., Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum. Pathol. 2010, 41:477-484.
14. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
15. Gallagher I.J., Scheele C., Keller P., Nielsen A.R., Remenyi J., Fischer C.P., Roder K., Babraj J., Wahlestedt C., Hutvagner G., et al. Integration of microRNA changes invivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med. 2010, 2:9.
16. Han T.W., Kato M., Xie S., Wu L.C., Mirzaei H., Pei J., Chen M., Xie Y., Allen J., Xiao G., McKnight S.L. Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell 2012, 149:768-779.
17. Hansen T.V., Hammer N.A., Nielsen J., Madsen M., Dalbaeck C., Wewer U.M., Christiansen J., Nielsen F.C. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol. Cell. Biol. 2004, 24:4448-4464.
18. Hartmann E.M., Beà S., Navarro A., Trapp V., Campo E., Ott G., Rosenwald A. Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression. Mod. Pathol. 2012, 25:1227-1235.
19. Heo I., Joo C., Cho J., Ha M., Han J., Kim V.N. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol. Cell 2008, 32:276-284.
20. Hoffmann N.E., Sheinin Y., Lohse C.M., Parker A.S., Leibovich B.C., Jiang Z., Kwon E.D. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008, 112:1471-1479.
21. Hu X., Guo J., Zheng L., Li C., Zheng T.M., Tanyi J.L., Liang S., Benedetto C., Mitidieri M., Katsaros D., et al. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol. Cancer Res. 2013, 11:240-250.
22. Jeng Y.M., Chang C.C., Hu F.C., Chou H.Y., Kao H.L., Wang T.H., Hsu H.C. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 2008, 48:1118-1127.
23. Jiang Z., Chu P.G., Woda B.A., Liu Q., Balaji K.C., Rock K.L., Wu C.L. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin. Cancer Res. 2008, 14:5579-5584.
24. Jiang Z., Lohse C.M., Chu P.G., Wu C.L., Woda B.A., Rock K.L., Kwon E.D. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008, 112:2676-2682.
25. Jønson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen Tv., Borup R., Johnsen A.H., Christiansen J., Nielsen F.C. Molecular composition of IMP1 ribonucleoprotein granules. Mol. Cell. Proteomics 2007, 6:798-811.
26. Jønson L., Nielsen F.C., Christiansen J. Isolation of RNP granules. Methods Mol. Biol. 2011, 703:265-273.
27. Kapoor S. IMP3: a new and important biomarker of systemic malignancies. Clin. Cancer Res. 2008, 14:5640. author reply 5640-5641.
28. Kato M., Han T.W., Xie S., Shi K., Du X., Wu L.C., Mirzaei H., Goldsmith E.J., Longgood J., Pei J., et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 2012, 149:753-767.
29. Kim K.Y., Cha I.H. A novel algorithm for lymph node status prediction of oral cancer before surgery. Oral Oncol. 2011, 47:1069-1073.
30. Kim K.Y., Li S., Cha J.D., Zhang X., Cha I.H. Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck 2012, 34:929-936.
31. Köbel M., Xu H., Bourne P.A., Spaulding B.O., Shih IeM., Mao T.L., Soslow R.A., Ewanowich C.A., Kalloger S.E., Mehl E., et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod. Pathol. 2009, 22:469-475.
32. Lee Y.S., Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007, 21:1025-1030.
33. Li S., Cha J., Kim J., Kim K.Y., Kim H.J., Nam W., Cha I.H. Insulin-like growth factor II mRNA-binding protein 3: a novel prognostic biomarker for oral squamous cell carcinoma. Head Neck 2011, 33:368-374.
34. Li Z., Gilbert J.A., Zhang Y., Zhang M., Qiu Q., Ramanujan K., Shavlakadze T., Eash J.K., Scaramozza A., Goddeeris M.M., et al. An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. Dev. Cell 2012, 23:1176-1188.
35. Lochhead P., Imamura Y., Morikawa T., Kuchiba A., Yamauchi M., Liao X., Qian Z.R., Nishihara R., Wu K., Meyerhardt J.A., et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur. J. Cancer 2012, 48:3405-3413.
36. Lu D., Yang X., Jiang N.Y., Woda B.A., Liu Q., Dresser K., Mercurio A.M., Rock K.L., Jiang Z. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am. J. Surg. Pathol. 2011, 35:1638-1645.
37. Mayr C., Hemann M.T., Bartel D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007, 315:1576-1579.
38. McGinnis J.L., Dunkle J.A., Cate J.H., Weeks K.M. The mechanisms of RNA SHAPE chemistry. J.Am. Chem. Soc. 2012, 134:6617-6624.
39. Mentrikoski M.J., Ma L., Pryor J.G., McMahon L.A., Yang Q., Spaulding B.O., Scott G.A., Wang H.L., Xu H. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod. Pathol. 2009, 22:1582-1587.
40. Mhawech-Fauceglia P., Herrmann F.R., Rai H., Tchabo N., Lele S., Izevbaye I., Odunsi K., Cheney R.T. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am. J. Clin. Pathol. 2010, 133:899-908.
41. Molenaar J.J., Domingo-Fernández R., Ebus M.E., Lindner S., Koster J., Drabek K., Mestdagh P., van Sluis P., Valentijn L.J., van Nes J., et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat. Genet. 2012, 44:1199-1206.
42. Nielsen F.C., Christiansen J. Endonucleolysis in the turnover of insulin-like growth factor II mRNA. J.Biol. Chem. 1992, 267:19404-19411.
43. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., Nielsen F.C. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell. Biol. 1999, 19:1262-1270.
44. Nielsen F.C., Nielsen J., Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand. J. Clin. Lab. Invest. Suppl. 2001, 234:93-99.
45. Nielsen F.C., Nielsen J., Kristensen M.A., Koch G., Christiansen J. Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH domains. J.Cell Sci. 2002, 115:2087-2097.
46. Nielsen J., Kristensen M.A., Willemoës M., Nielsen F.C., Christiansen J. Sequential dimerization of human zipcode-binding protein IMP1 on RNA: a cooperative mechanism providing RNP stability. Nucleic Acids Res. 2004, 32:4368-4376.
47. Park S.M., Shell S., Radjabi A.R., Schickel R., Feig C., Boyerinas B., Dinulescu D.M., Lengyel E., Peter M.E. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007, 6:2585-2590.
48. Rüdel S., Flatley A., Weinmann L., Kremmer E., Meister G. A multifunctional human Argonaute2-specific monoclonal antibody. RNA 2008, 14:1244-1253.
49. Runge S., Nielsen F.C., Nielsen J., Lykke-Andersen J., Wewer U.M., Christiansen J. H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. J.Biol. Chem. 2000, 275:29562-29569.
50. Schaeffer D.F., Owen D.R., Lim H.J., Buczkowski A.K., Chung S.W., Scudamore C.H., Huntsman D.G., Ng S.S., Owen D.A. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 2010, 10:59.
51. Schmitter D., Filkowski J., Sewer A., Pillai R.S., Oakeley E.J., Zavolan M., Svoboda P., Filipowicz W. Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. Nucleic Acids Res. 2006, 34:4801-4815.
52. Shinoda G., Shyh-Chang N., de Soysa T.Y., Zhu H., Seligson M.T., Shah S.P., Abo-Sido N., Yabuuchi A., Hagan J.P., Gregory R.I., et al. Fetal deficiency of Lin28 programs life-long aberrations in growth and glucose metabolism. Stem Cells 2013, 31:1563-1573.
53. Sitnikova L., Mendese G., Liu Q., Woda B.A., Lu D., Dresser K., Mohanty S., Rock K.L., Jiang Z. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin. Cancer Res. 2008, 14:1701-1706.
54. Speese S.D., Ashley J., Jokhi V., Nunnari J., Barria R., Li Y., Ataman B., Koon A., Chang Y.T., Li Q., et al. Nuclear envelope budding enables large ribonucleoprotein particle export during synaptic Wnt signaling. Cell 2012, 149:832-846.
55. Szarvas T., vom Dorp F., Niedworok C., Melchior-Becker A., Fischer J.W., Singer B.B., Reis H., Bánkfalvi A., Schmid K.W., Romics I., et al. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU Int. 2012, 110(6 Pt B):E308-E317.
56. Tessier C.R., Doyle G.A., Clark B.A., Pitot H.C., Ross J. Mammary tumor induction in transgenic mice expressing an RNA-binding protein. Cancer Res. 2004, 64:209-214.
57. Thornton J.E., Gregory R.I. How does Lin28 let-7 control development and disease?. Trends Cell Biol. 2012, 22:474-482.
58. van Kouwenhove M., Kedde M., Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat. Rev. Cancer 2011, 11:644-656.
59. Viswanathan S.R., Daley G.Q., Gregory R.I. Selective blockade of microRNA processing by Lin28. Science 2008, 320:97-100.
60. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41:843-848.
61. Wagner M., Kunsch S., Duerschmied D., Beil M., Adler G., Mueller F., Gress T.M. Transgenic overexpression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas. Gastroenterology 2003, 124:1901-1914.
62. Walter O., Prasad M., Lu S., Quinlan R.M., Edmiston K.L., Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum. Pathol. 2009, 40:1528-1533.
63. Weber S.C., Brangwynne C.P. Getting RNA and protein in phase. Cell 2012, 149:1188-1191.
64. Yang D.H., Moss E.G. Temporally regulated expression of Lin-28 in diverse tissues of the developing mouse. Gene Expr. Patterns 2003, 3:719-726.
65. Yantiss R.K., Cosar E., Fischer A.H. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008, 52:133-138.
66. Yuan R.H., Wang C.C., Chou C.C., Chang K.J., Lee P.H., Jeng Y.M. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann. Surg. Oncol. 2009, 16:1711-1719.
67. Yun J., Frankenberger C.A., Kuo W.L., Boelens M.C., Eves E.M., Cheng N., Liang H., Li W.H., Ishwaran H., Minn A.J., Rosner M.R. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J. 2011, 30:4500-4514.
68. Zhou X., Benson K.F., Ashar H.R., Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995, 376:771-774.
69. Zhu H., Shyh-Chang N., Segrè A.V., Shinoda G., Shah S.P., Einhorn W.S., Takeuchi A., Engreitz J.M., Hagan J.P., Kharas M.G., et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011, 147:81-94. DIAGRAM Consortium, MAGIC Investigators.MAGIC Investigators.